Modality
Small Molecule
MOA
HER2
Target
WEE1
Pathway
JAK/STAT
Parkinson's
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
→ Jun 2029
Phase 2Current
NCT07270600
2,427 pts·Parkinson's
2018-02→2029-06·Recruiting
2,427 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-06-183.2y awayPh2 Data· Parkinson's
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2
Recruit…
Catalysts
Ph2 Data
2029-06-18 · 3.2y away
Parkinson's
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07270600 | Phase 2 | Parkinson's | Recruiting | 2427 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 |